



Mini MIXiii Miami

Health-Tech.IL Organized and Led by IATI



Israeli Innovation Shaping Global Health-Tech

January 9th 2025, The LAB Miami

*Fostering the Resilience, Global Competitiveness
and the Business Continuity of Israel's Tech Industries*

Powered by:



Local Partner:



Sponsored by:



Supported by:



Collaborated by:



*The Umbrella Association of Israel's Tech Industries (NGO)
Fostering the Resilience, Global Competitiveness and the Business Continuity of
Israel's Tech Industries*

Tech Multi Nationals



Health Multi Nationals



Israeli Growth & Mature Companies



Hospitals, TTO's & Academia



Venture Capital & Investment Funds



Services



IATI | Medinat Ha'Yehudim 89, Bldg E | Herzliya Pituach | Israel | iati@iati.co.il

Dear Participants,

Welcome to the IATI Mini MIXiii Miami 2025, in which an exclusive symposium of 19 Israeli prominent startups from Israel's Health-Tech and Life Sciences industry will be showcasing their activities on stage, and with South Florida's health ecosystem will push the frontier for collaboration for the sake of worldwide wellbeing.

I would like to thank the participants that comprise this symposium. As Israel's Umbrella Association of the Tech industries, IATI will continue to connect and promote Israel's most valuable resource – the skills and brain power of our human capital – to make a real difference in creating a better future for generations to come.

Israel and the US have a very tight relationship that we seek to foster and nourish with unique global initiatives like this. I earnestly believe in a future where Israel's and Miami's Life Science ecosystem work hand in hand, and the seeds of this relationship are sown in this gathering of visionaries.

While it has been a challenging year, Israel's advanced technology industries have proved their fortitude and resilience. With an optimistic rise towards the latter half of 2024 and future prospects for 2025, IATI's ability to guarantee business certainty and continuity is reinforced.

This unique opportunity serves as a steppingstone for our annual MIXiii, and I hereby invite all participants to join us in the MIXiii Health-Tech.IL Annual Conference which will be held in ICC Jerusalem on March 4th – 5th, 2025. This conference serves as the premier conference and exhibition in the field of Life Science and Health-tech in Israel which aims to bring together leading start-ups and mature companies, hospitals, investors and academia from around the globe.

I would like to extend my gratitude to Dr. Maurice Ferre Chair of our Mini MIXiii Miami and Insightech CEO; Yaacov Michlin Chair of MIXiii and Biolight CEO and Mati Gil Head of Steering Committee and AION Lab CEO.

I would like to thank our partners and supporters: Amazon Web Services (AWS); Miami_Israel Collective; the LAB, Miami; Israel Export Institute; Accelmed ventures; Ceros; Sullivan & Worcester; IDB Bank; Tel-Aviv Sourasky Medical Center Ichilov; Sheba Tel Hashomer; Select Florida; eMerge Americas and Endeavor, for making this all possible.

Sincerely,

Karin Mayer Rubinstein

CEO & President

Israel Advanced Technology Industries Association (IATI)

As the leader of the Life Sciences sector at IATI and chairman of MIXiii Health-Tech.IL Conference it is an honor for me to welcome you all to our Mini MIXiii event in Miami.

MIXiii Health-Tech.IL Conference taking place in Jerusalem 4-5 March, 2025 is the premier health conference in Israel where global experts, innovators, and thought leaders converge to shape the future of health and wellness. MIXiii allows participants around the globe physically and virtually explore first hand groundbreaking research, cutting-edge technology, and practical strategies to enhance physical, mental, and emotional well-being and rehabilitation. Mixiii is the only conference made by the industry and for the industry.

The Mini MIXiii Miami on January 9, is an exclusive symposium that will feature 19 promising Israeli Health-Tech startups, carefully selected by our esteemed steering committee. The CEOs of these companies will deliver pitches and present their activities on stage at the Mini MIXiii Miami.

These startups are on the cutting edge of innovation, with groundbreaking technologies spanning AI-driven drug discovery, digital health solutions, advanced diagnostics, medical devices, and biotech advancements.

This symposium offers a unique opportunity to explore potential collaborations, partnerships, and funding prospects with some of Israel's brightest minds and most pioneering companies but this is just a taste and promo to our main MIXiii annual conference that last year brought to Jerusalem over 1500 participants from 30 countries with hundreds of start ups.

I personally recommend you make the most of the interactions in Miami and plan not to miss this unparalleled opportunity to be part of a transformative experience in health and wellness in Jerusalem. Reserve your spot now for MIXiii.com and take a step toward a healthier tomorrow! The Biomed space in Israel will be one of the growth engines in the blooming economy forecasted for Israel. Join us in this journey.

Yaacov Michlin

CEO, Biolight Life Sciences

Chairman, MIXiii Health-Tech.IL

Innovation arises from a unique convergence of circumstances, and Miami is the ideal crossroads where Israeli health-tech excellence meets global opportunity. As Chair of the IATI Mini MIXiii Miami 2025 Symposium, I am thrilled to welcome you to this exclusive event, which brings together visionary leaders, groundbreaking startups, and forward-thinking investors.

This symposium celebrates 19 of Israel's most promising health-tech companies, showcasing cutting-edge advancements in AI-driven drug discovery, digital health, diagnostics, medical devices, and biotech. Their work offers new solutions that promise to improve healthcare outcomes both here in South Florida and around the world.

Miami's position as a hub for innovation makes it the perfect setting to foster these critical partnerships. I invite you to engage fully in this unique opportunity to drive meaningful collaborations and accelerate the future of health tech.

Thank you Karin Mayer Rubinstein and IATI team for the vision and for making it happen in Miami for the first time.

Warm regards,

Dr. Maurice R. Ferré

Chairman and CEO, Insightec

Chairman, IATI Mini MIXiii Miami 2025

Welcome to Miami!

I am delighted to welcome you to this exclusive gathering of IATI Mini-MIXiii Miami.

Our mission is to build a bridge between two great ecosystems to bring together innovative Israeli health technologies with great Miami partners and shape the future of healthcare.

Today, you will have the opportunity to meet with 19 of Israel's leading Health Tech startups, meticulously selected by the IATI Steering Committee, which comprises top Health-Tech investors in Israel.

We encourage you to explore partnership, funding, and commercialization opportunities with these companies that are at the forefront of Digital Health, Diagnostics, Devices, Biotech, and using AI for Drug Discovery and Development.

Thank you for joining us at IATI Mini MIXiii Miami.

Together, let's make an impact for Israel, for Miami, and for patients around the world.

Mati Gill

CEO, AION Labs

Head of Steering Committee, IATI Mini MIXiii Miami

Dear Friends,

It is my honor to welcome you to the IATI Mini MIXiii Symposium in Miami, a dynamic platform showcasing the groundbreaking innovations that make Israel a global leader in health technology.

The strong and flourishing bond between Israel and Florida has never been more evident. With escalating business collaborations, particularly in the health-tech sector, our partnership is transforming ideas into impactful solutions.

Israel's economy, a beacon of resilience and innovation, thrives on its entrepreneurial spirit. As we face global challenges, our commitment to creating transformative technologies is unwavering.

We look forward to fostering even deeper cooperation, strengthening ties, and building a future where innovation and collaboration know no bounds.

Warm regards,

Maor Elbaz-Starinsky

Consul General of Israel

Miami

Dear Attendees,

On behalf of the Israel Export Institute, I am delighted to welcome you to the IATI Mini MIXiii Miami Symposium.

This event provides a unique opportunity to explore Israeli innovations across various sectors, reflecting the creativity and technological excellence that Israel is known for in Health-Tech.

The Israel Export Institute is committed to fostering global business connections, supporting Israeli companies in expanding their presence worldwide, and driving international collaboration and providing free of charge scouting services for any investor or foreign player that is interested to explore Israeli Innovation.

Through a wide range of activities, including trade missions, exhibitions, and strategic partnerships, we strive to empower Israeli businesses and promote Israeli innovation on a global scale.

We are excited to support and collaborate with IATI at this dynamic gathering in Miami and hope to see new partnerships and collaborations developing from the event.

All the best,

Nili Shalev

CEO

Israel Export Institute

THE INTERNATIONAL LIFE SCIENCE & HEALTH-TECH WEEK IN ISRAEL

Conference | Exhibition | Networking
Startup Competition

Special researchers' day
March 3, 2025
The Hebrew University

Main event
March 4-5, 2025
ICC Jerusalem



SCAN FOR WEBSITE

MARK YOUR CALENDARS

WE ARE HONORED TO ANNOUNCE THE PREMIER LEADING INTERNATIONAL CONFERENCE OF THE HEALTH-TECH ECOSYSTEM IN ISRAEL
THE ONLY HEALTH-TECH CONFERENCE IN ISRAEL BY THE INDUSTRY FOR THE INDUSTRY

CONFERENCE TOPICS

DIGITAL HEALTH STARTUP COMPETITION	BREAKTHROUGH INNOVATION IN CANCER TREATMENT	AI AND DRUGS RESEARCH	BEYOND LIMITS: CUTTING EDGE TECH IN REHABILITATION	DIGITAL HEALTH SESSION	OIS ISRAEL – INNOVATION IN OPHTHALMOLOGY
PARTICIPANTS ~1700		SPEAKERS ~200		2 PLENARY SESSIONS, 9 BREAKOUTS 2 DAYS	

In Cooperation:

In Partnership:

Diamond Sponsor:

Platinum Sponsor:

Gold Sponsors:







Silver Sponsors:

Supported by:

In Collaboration:

Meet the Companies

In alphabetical order

	<p>AIDOC</p> <p>Aidoc is a pioneering force in clinical AI. Powered by Aidoc's proprietary aiOS™, we analyze and aggregate medical data to enable care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Aidoc AI is always on, running in the background to change the foreground.</p> <p>www.aidoc.com</p>	 <p>Elad Walach CEO</p>
	<p>AISAP</p> <p>AISAP LTD is a pioneering company at the intersection of AI and healthcare with a mission to transform care delivery through its flagship product, AISAP POCAD™ (Point-of-Care Assisted Diagnosis). The platform enables clinicians to perform comprehensive, AI-powered ultrasound diagnostics anywhere, anytime.</p> <p>www.aisap.ai</p>	 <p>Roni Attali, PhD CSO and US-GM</p>
	<p>BioBeat</p> <p>Biobeat, a med-tech company, providing FDA-cleared, cuff-less blood pressure monitoring using a small, non-invasive chest sensor. This patented technology captures blood pressure, heart rate, and cardiac output, enabling clinicians to quickly evaluate and adjust treatment plans.</p> <p>www.bio-beat.com</p>	 <p>Arik Ben Ishay CEO</p>



Briya

Briya revolutionizes healthcare data access by creating a seamless, real-time platform that connects diverse systems and standardizes patient-level data. It accelerates research, fosters innovation, and enables real-world evidence generation while ensuring 100% privacy and compliance.

www.briya.com



David Lazerson

Co-Founder and CEO



Cordio Medical

Cordio developed the HearO- software as medical device, an FDA breakthrough device designated system. It's a medical-grade digital platform that enables heart failure monitoring through AI assisted advanced speech analysis technology. Transforming standard mobile devices into advanced medical devices. HearO have strong endorsement by providers, integrated health system and value based care systems.

www.cordio-med.com



Tamir Tal

CEO



EyeControl

EyeControl is a pioneering medical tech startup specializing in acute care, using AI and eye-tracking wearables to enhance patient communication and ICU Delirium management. Our FDA-listed, CE-marked platform connects patients, families, and medical teams, reducing healthcare burden and improving outcomes.

www.eyecontrol.co.il



Or Retzkin

CEO



Gero3D

Gero3D is on a mission to revolutionize orthopedic care by replacing traditional plaster casts with personalized 3D-printed solutions.



Our end-to-end platform simplifies the process from scanning to ordering, allowing healthcare professionals to focus on patient care.



www.Gero3d.com





Nadav Ichay

Co- Founder & CEO

	<p>Imagene Imagene advances precision oncology with AI-powered solutions that decode cancer from biopsy images.</p> <p>Our Oncology Intelligence Suite leverages a state-of-the-art vision foundation model, delivering fast, user-friendly, and data-efficient AI to accelerate discoveries and advance drugs into the clinic.</p> <p>www.imagene-ai.com</p>	 <p>Dean Bitan Co-Founder & CEO</p>
---	---	--

	<p>Kahun Kahun leverages its knowledge structuring technology to enable GenAI for clinical content, ensuring accurate matching of clinical queries with medical sources. Used by healthcare professionals in pharma and healthcare systems, Kahun's AI chatbot delivers evidence-based answers from structured knowledge.</p> <p>www.kahun.com</p>	 <p>Dr. Michal Tzuchman-Katz CEO and Co-Founder</p>
---	---	---

	<p>Kamari Pharma Kamari pharma is a clinical stage company developing drugs for rare and severe genetic skin disorders, based on proprietary TRPV3 inhibitors. Clinical studies in patients demonstrated promising results. Kamari is the leader in developing treatments for these orphan untreated indications.</p> <p>www.kamaripharma.com</p>	 <p>David Aviezer, PhD Chairman & CEO</p>
---	---	--



Longevity AI

Longevity AI is a one-stop-shop operating system designed for proactive care. From annual physicals to concierge medicine, Longevity AI delivers tailored practice management across the preventive care spectrum. Our AI-powered dashboard and member app enable care teams to consolidate data from diverse sources and automatically generate a cohesive longevity plan - focused on chronic disease prevention and health optimization.

www.longevity-ai.com



Guy Leitersdorf

Founder & CEO



MeMed

MeMed's mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed. The MeMed BV® test measures host-immune response proteins to accurately determine the likelihood of bacterial or viral infections in minutes.

www.MeMed.com



Troy Boutelle

General Manager,
MeMed US Founder



Momentis

Momentis Surgical is transforming the field of robotic surgery by developing innovative small footprint, cost-effective, robotic-assisted technologies for a growing number of clinical applications. Our goal is to empower surgeons to perform minimally invasive procedures to enable better patient outcomes.

www.momentissurgical.com



Dvir Cohen

CEO



Opmed.Ai

Opmed.ai offers AI-driven solutions to optimize operating room (OR) scheduling and management. The platform uses network science and advanced algorithms to enhance resource utilization, minimize downtime, and build resilient OR schedules. Key features include predictive intelligence for accurate case duration predictions, seamless integration with existing systems, and customization based on specific constraints and preferences. .

www.Opmed.ai



Mor Brokman, PhD

Co-Founder and CEO



minimum variance. maximum care.

Project M

Project M uses clinical data to chart the best patient treatment, that is optimized for outcomes and cost. We do it in real-time and individually for a patient utilizing causal AI tools. Additionally, we provide management with a retrospective simulator.

www.linkedin.com/company/projectmai



Danny Glushenkov

Co-CEO



data beats intuition™

Theator

Theator is focused on improving surgical outcomes through its AI-powered Surgical Intelligence Platform. The platform captures and analyzes surgical video and leverages advanced computer vision and AI to identify critical moments during procedures that impact quality, safety, operational efficiency, education, and documentation workflows. Theator's innovations aim to shatter today's reality: "where you live determines if you live" by reducing surgical variability, disseminating best practices, enhancing operational efficiency, and promoting better patient outcomes.

www.theator.io



Tamir Wolf MD, PhD

Co-founder and CEO



UltraSight

UltraSight is at the forefront of cardiology, revolutionizing cardiac ultrasound through the power of artificial intelligence (AI). Our mission is to increase patient access to cardiac care by enabling more healthcare professionals to perform cardiac ultrasound in any care setting.

www.ultrasight.com



Davidi Vortman

CEO



PromiseBio

Promise Bio

Promise Bio is transforming precision medicine for immune-mediated diseases with a first-of-its-kind cloud-based platform that analyzes post-translational modifications at scale. We identify biomarkers for treatment response to stratify previously inseparable patient groups, optimize treatment decisions, and enhance drug development.

www.promise.bio



Ronel Veksler MD, PhD

Co-Founder & CEO



Visci

Vi-Sci's innovative Eye-D technology treats glaucoma by the insertion of a sub-conjunctival implant, which releases the prescribed medication "Latanaprost", in sustained release manner, eliminating the need to use eye drops, a daily challenge for the aged. The implant; an in-office medical procedure is developed by ViSci, branded as VS-101, is licensed for global use and is in its development phase.

www.bio-light.co.il/visci-2



Yaacov Michlin

Chairman



Aidoc is a pioneering force in clinical AI. Powered by our proprietary aiOS™, we analyze and aggregate medical data to enable care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Aidoc AI is always on, running in the background to change the foreground.

HEALTHCARE REALITIES TODAY



Rising Costs

Total expenses up 19%, driven by inflation and labor shortages¹



Missed Revenue Potential

Less than 40% of providers adhere to radiologist recommendations for follow-up exams²



Overlooked Diagnosis

1 in 18 ED patients receive an incorrect diagnosis³

IMPACTING PATIENTS AND CARE TEAMS

26%

Reduction in LoS
Cedars-Sinai, PE⁴

9.8%

Reduction in ED LoS
Yale New Haven Health, ICH⁵

55%

Turnaround Time Reduction
University of Rochester, ICH⁶

THE AIDOC DIFFERENCE

Exclusive aiOS™ Platform

- **Timely:** Fully automated 24/7 monitoring and notification
- **Interconnected:** Real-time alerts of time-sensitive cases, built-in risk stratification and a mobile imaging viewer to facilitate cross-department communication
- **Scalable:** A single platform that integrates within native workflow and IT infrastructure

Built for Integrations

- Reliably deploy and run enterprise AI at scale from a unified platform that coordinates and deploys algorithms, connects to existing systems (PACS, EHR, scheduling, etc.) and creates a seamless user experience

Largest Library of FDA-cleared Algorithms

- 17 FDA-cleared Aidoc developed algorithms, plus seven partner apps
- Solutions covering 75% of patient populations

Aidoc Impact

- Used in more than 1,000 medical centers
- 3M patients analyzed each month
- 130+ clinical studies

See what Aidoc can do at your facility.

1. National Hospital Flash Report: December 2022 | Kaufman Hall. (2023, January 4). <https://www.kaufmanhall.com/insights/research-report/national-hospital-flash-report-december-2022> 2. Hansra, S. S., Loehfelm, T. W., Wilson, M., & Corwin, M. T. (2021). Factors Affecting Adherence to Recommendations for Additional Imaging of Incidental Findings in Radiology Reports. *Journal of the American College of Radiology*, 18(2), 233–239. <https://doi.org/10.1016/j.jacr.2020.02.021> 3. Diagnostic Errors in the Emergency Department: A Systematic Review. (n.d.). Effective Health Care (EHC) Program. <https://effectivehealthcare.ahrq.gov/products/diagnostic-errors-emergency/research> 4. Petry M, Lansky C, Chodakiewitz Y, Maya M, Pressman B. Decreased Hospital Length of Stay for ICH and PE after Adoption of an Artificial Intelligence-Augmented Radiological Worklist Triage System. *Radiol Res Pract*. 2022;2022:2141839. Published 2022 Aug 18. doi:10.1155/2022/2141839 5. Davis, M. J., Rao, B. M., Cedeño, P. A., Saha, A., & Zohrabian, V. M. (2020). Machine Learning and Improved Quality Metrics in Acute Intracranial Hemorrhage by Noncontrast Computed Tomography. *Current Problems in Diagnostic Radiology*, 51(4), 556–561. <https://doi.org/10.1067/j.cpradiol.2020.10.007> 6. Wismueller et al. (2020) A Prospective Randomized Clinical Trial for Measuring Radiology Study Reporting Time on Artificial Intelligence-Based Detection of Intracranial Hemorrhage in Emergent Care Head CT. *Proceedings Volume 11317, Medical Imaging 2020: Biomedical Applications in Molecular, Structural, and Functional Imaging*; 113170M doi: 10.1117/12.2552400









Improve the delivery of ultrasound diagnosis with advanced AI at the Point of Care. Anytime, Anywhere.

Revolutionizing Ultrasound at the Point of Care

AISAP supports clinicians using Point-of-Care Ultrasound with a comprehensive solution that streamlines the ultrasound workflow, improves acquisition quality, enables immediate interpretation and facilitates accurate diagnoses leading to exceptional clinical outcomes and healthcare efficiency.

Value Proposition

-  Empowering Clinicians to Assess Cardiac Health in Real-Time
-  Extending Advanced Cardiac Ultrasound to Underserved facilities
-  Accelerating Time to Diagnosis and Reducing Hospital Stays
-  Key Cardiac Metrics at Clinicians' Fingertips
-  Facilitating non-invasive screening to detect risk conditions
-  Enhancing Patient Safety and Satisfaction
-  Increased hospital procedures & POCUS Billing

About AISAP

AISAP LTD is a pioneering company at the intersection of AI and healthcare with a mission to transform healthcare delivery through its flagship product, AISAP CARDIO (FDA cleared), which for the first time delivers POCAD™ - Point-of-Care Assisted Diagnosis.

The 1st package is echocardiography, that was trained on hundreds of thousands of studies comprising over 24 million echo video clips. AISAP's novel algorithms on POCUS devices has been validated in multi-national, multi-site clinical trials at Mass General Brigham, Thomas Jefferson University Hospital, Mayo Clinic, Inova Fairfax Medical Campus.



Contact us





Cuffless Blood Pressure Monitoring Leaders in Hypertension Monitoring Unmask the Silent Killer



Biobeat Technologies

Biobeat is a med-tech company providing FDA-cleared, cuff-less blood pressure monitoring. The small, non-invasive sensor is placed onto the patient's chest for 24 hours, and the measurements are taken through our proprietary patented PPG sensor. The technology not only allows for blood pressure to be taken, but also extracts heart rate, and cardiac output. The device and automated platform deliver a detailed report to the clinician, immediately after the patient has completed the test. This allows for quick evaluation and treatment plans, and also enables physicians to make proper adjustments on current treatment plans based

on the quantitative measures and trends that the blood pressure monitoring solution provides. The Biobeat sensor avoids the effect of white coat and masked hypertension by using a cuff-less test. White coat hypertension is a common barrier in Blood Pressure Monitoring testing, as patients often become stressed when the cuff inflates.

However, with Biobeat, patients often forget they are wearing the sensor and do not feel when the readings are being taken. This allows them to go about their daily lives without interruption. Founded in 2016, Biobeat is headquartered in Petah Tikva, Israel.

ACC/AHA Hypertension Guidelines:

Class Ia recommendation to confirm the diagnosis of hypertension with 24 hour monitoring

Guideline Supported Consistent Unnoticed Monitoring



Advanced 24 hour hypertension monitoring



Allows for uninterrupted sleep while obtaining nighttime measurements



Avoids the effect of white coat syndrome and masked hypertension



Eliminates patient anxiety due to upcoming readings

Comfort Drives Patient Compliance

- Patch is **easy to apply** and **comfortable** for the patient
- **User-friendly design** ensures simple training for staff
- Unequivocal **patient preference** over traditional options



Devise a Thorough Treatment Plan with a Reimbursement Pathway

- Automatically generated report **available within minute** after the completion of the 24-hour monitoring period
- Existing reimbursement codes for 24 hour monitoring: 93784, 93786, 93788, 93790.



Validated against gold standard cuff-based 24 hour hypertension monitoring published in the American Journal of Hypertension

Contact us to schedule a demo and learn more about how Biobeat can elevate your healthcare practice!

✉ info@bio-beat.com 🌐 Bio-beat.com [in](https://www.linkedin.com/company/biobeat) Biobeat Ltd



Better data, better health.

Unlock the full value of your data

Join leading hospitals, clinics, and health systems in redefining real-world data access and retrieval to drive medical innovation.



Lead and collaborate in global research and innovation

Briya paves the way for healthcare providers to participate in high-profile global research and innovation fields, attracting top talent and improving care with tailored AI solutions.



Enhance in-house visibility and boost internal research

Boost operational efficiency by querying internal data silos with Briya, leveraging AI for enhanced visibility and reducing reliance on expensive analysis resources and manual efforts.



Make your data worth more

Increase the value of your data for research and capitalize on it. Briya's technology enables a comprehensive longitudinal and horizontal view of the patient journey through data collaborations.



Enhance sponsored research opportunities

Harness the power of Briya's extensive network, comprising pharmaceutical and research partnerships, all while safeguarding patient privacy and ensuring compliance.



On premise integration

- A decentralized on-premise swiftly integrated solution, where hospitals preserve full control over their data.
- Briya-proprietary connectors, flawlessly link the data in real-time at the patient level using zero-knowledge proof (ZKP) algorithm, making the data complete and longitudinal at the highest quality.
- Briya supports interconnection of multiple sites.



Real-time data retrieval

- Based on in-query real-time data retrieval and on-the-fly De-identification approach.
- Seamless and safe - rapid integration with the data at the source, with no replication.
- Always up-to-date data, accurate results without wrong preliminary assumptions.
- Bulletproof anonymity with real-time prevention of identification attempts (based on top-notch fraud detection algorithms).



Regulations auto enforced

- Privacy Policies, Data Use Agreements and patient consent automatically enforced using smart contracts.
- Smart contracts enforce compliance cryptographically so it is impossible to share restricted information on the network, only permitting access and transmission to authorized entities.



Join us to drive health innovation at scale
info@briya.com | Briya.com

Need

Over 22 million people (with 6.7M Americans patients), in the Western world have congestive heart failure (CHF). Carefully managing congestion (fluid levels) is vital to keep this population out of hospitals. Easy to use, accurate mentoring tools to guide treatment to reduce readmissions are not readily available. As a result, CHF is the most prevalent and costly condition in the world with ~1.1M hospitalizations/year and ~\$40B direct costs in the US alone.

Solution

Cordio Medical, an Israeli startup developed HearO, a groundbreaking, non-invasive monitoring solution based on analyzing subtle changes in the patient's speech sampled on the patient's smartphone. The speech samples are sent to Cordio's cloud-based analytical engine via the HearO app. Cordio's solution provides early warning of changes in the patient's condition, allowing medication to be adjusted before the patient needs to be hospitalized.

Management Team

Cordio Medical was founded by Prof. Chaim Lotan, a renowned cardiologist and led by CEO Tamir Tal with vast experience with successful startups in the cardiac space, CTO Prof. Ilan Shallom is a leading expert in speech signal processing, SVP Clinical and Regulation Dr. Ronit Haviv with innovative molecules and pharma experience and VP R&D Itai Katzir a senior signal processing and AI engineer and software as medical device expert.

IP

Cordio Technology is protected by an extensive IP portfolio that protects all the various aspects of the technology. The company has 14 inventions in total covered in patent applications, mostly in the US, Israel, Europe, Japan, China and South Korea.

Clinical & Regulatory

HearO was used by more than 1500 patients and is already a CE certified medical device. HearO was designated a Breakthrough Device status by the FDA. US DETECT-HF FDA pivotal study is in final stages in more than 40 US centers with FDA approval expected H1 2025. Our COMMUNITY-HF study results demonstrate a sensitivity of ca. 80% detecting events 25 days on average before a heart failure event is happening.

Reimbursement and US market Potential


HearO indication as approved by the FDA is covered by CPT codes that allow very high coverage rate of Medicare (and Medicare Advantage) and 90% of private payers. As a result, Cordio business model- SaaS/PMPM is beneficial for both payers and providers. Hearo being software as medical device does not have a capital expense component which is advantageous for providers. Potential market based on the HearO reimbursement in US \$7B yearly recurring revenues.

US Commercial Launch

Cordio has traction with Fortune 500 companies that are looking into M&A opportunity. The company is working toward our US launch and already identified potential cardiac clinics, provider network and integrated system that are engaging with Cordio toward commercial implementation of the HearO system immediately post FDA approval.

The First Personalized ICU Communication Platform

EyeControl is an **AI-powered wearable device** that uses eye-tracking and conversational technology to enable 24/7 personalized, bidirectional communication and monitoring. Designed for ICU and acute care settings, it adapts to each patient's cognitive and awareness levels, providing a first-of-its-kind solution for enhancing care and connection. Additionally, the system integrates key components of the **A-F bundle**, a set of evidence-based practices proven to improve outcomes, decrease hospital stays, and reduce costs for ICU patients.



Clinical Trials Partners

We are conducting multi-center and single-center clinical trials in collaboration with major hospitals across the US and Israel, measuring the device's ability to manage and reduce delirium.



Beth Israel Deaconess Medical Center



RABIN MEDICAL CENTER
BEILINSON • HASHARON



JOHNS HOPKINS
MEDICINE

Commercial Highlights

EyeControl is already used by hundreds of patients, families, and healthcare providers



First US Commercial Pilots



IP: 4 Patent Families



Official Supplier of Israel's Largest HMO

EyeControl- Med is FDA-listed and CE-marked as a communication platform; it is ISO-certified and HIPAA-compliant.



Transforming orthopedic care with Gero3D unique technology.

Custom-fit 3D-printed solutions tailored precisely to each patient's needs.



How it works



1st visit

Perform a 3D scan and apply a temporary Gero3D cast (1:30 minutes)



2nd visit

Replace the temporary cast with the long-term Gero3D cast (30 seconds)



3rd visit

Remove the Gero3D cast (30 seconds)

Value for clinics

✔ Time Savings

Faster application and removal compared to traditional casts (scan to order – 1 min).

✔ Skilled Staff Not Required

Gero3D technology simplifies the entire casting process, reducing the need for specialized training or skilled casting professionals.

✔ Reduced Complications

Gero3D's precision-fit casts lower the risks of pressure sores, skin issues, and misalignment, ensuring safer outcomes.

✔ Waste and Clean-up

Casting materials create additional waste and can be messy, requiring extra clean-up and storage space in the clinic.

Seamlessly Integrating into Clinics

✔ User-Friendly Technology

Intuitive software and equipment require minimal training, enabling general staff to handle orders with ease

✔ Efficient Ordering

A quick scan is all it takes—Gero3D takes care of everything else, delivering the cast directly to the clinic

✔ Hassle-Free Integration

Compact equipment and a streamlined workflow integrate effortlessly into existing clinic operations without major changes

✔ Zero Costs

Clinics receive scanning equipment (iPad, 3d scanner, and software) for free and pay only for completed orders.




Nadav Ichay, CEO

With more than 10 years of experience in 3D printing field, and after founded three companies, Nadav is fired up about the potential of merging 3D printing with medical wearables.



Eli Zerach, CTO

With over 8 years of experience, Eli has led diverse R&D teams in crafting cutting-edge, multidisciplinary products. Eli is a maker at heart and driven by the power of merging disciplines to revolutionize solutions that improve healthcare outcomes.





Imagene

Unlocking the Power of Oncology Intelligence to Transform Cancer Research & Diagnostics

Imagene is a pioneering company developing AI solutions to advance precision oncology. Our Oncology Intelligence translates complex tissue patterns into meaningful insights offering a deeper understanding of tumor microenvironments, disease mechanisms, and biomarker distributions.

CanvOI

A State-of-the-art Digital Pathology Foundation Model
Developed in partnership with Oracle & Ellison Medical Institute



CanvOI achieved industry-leading performance

OISuite

AI-Driven Hypothesis Generation
User-friendly and data-efficient AI for precision oncology research at scale




- Treatment response prediction
- Risk of disease recurrence
- Disease prognosis
- Biomarker discovery
- Histopathological features

SaaS enterprise platform enabling rapid development of a wide range of downstream applications even with minimal data.

LungOI™

Rapid Biomarker Profiling Test
The first AI-powered biomarker profiling test to identify actionable alterations in NSCLC patients



Our team brings together clinicians, scientists, computational biologists and AI experts, supported by renowned medical advisors and backed by leading investors.

www.imagene-ai.com



Clinical AI Powered by Structured Knowledge

Enabling the effective use of Generative AI for clinical content

Leveraging Knowledge structuring to overcome GenAI limitations

Kahun leverages its advanced knowledge structuring technology to uniquely module knowledge into a structured format, making clinical content ready for GenAI use. The structured knowledge serves as the basis to accurate matching of clinical queries with medical sources, enabling the effective use of GenAI for clinical content.

Kahun supports healthcare systems, pharma companies and medical publishers by structuring their medical knowledge, ensuring consistency and accuracy in outputs.

Who We Serve:

- ✔ **Healthcare providers:** Enhance decision-making and adherence to protocols and guidelines. Save time and promote better care
- ✔ **Pharma companies' commercial teams:** Enhancing clinical content generation, supporting planning and sales enablement.
- ✔ **Medical Publishers:** Setting a reliable infrastructure for the use of GenAI with the publisher's clinical content.

Key features & benefits

Transparent

Provides transparency into the origins of generated content and traceability of data

Highlights knowledge gaps

Helps with shaping education strategies

Matches clinical profiles

Key to generating reliable case-relevant responses in real-time

Compiles multiple sources

Responses take into account various clinical knowledge sources including proprietary content

Why knowledge structuring?

Knowledge structuring allows for precise matching between clinical queries and relevant content across various knowledge sources, enhancing the accuracy, transparency, and reliability of GenAI outputs, and ultimately leading to more effective AI-driven insights.

Enhancing healthcare professionals' access to knowledge through a chatbot

How it would work

1. Kahun would define a knowledge corpus (research papers, guidelines etc.)
2. The organization will be able to edit the corpus including adding proprietary content.
3. Kahun would automatically structure the knowledge.
4. Healthcare professionals will use the chatbot to ask general or case-specific questions and receive answers derived from the corpus.



- ✔ Accounts for high complexity cases
- ✔ Enables hierarchy between guidelines
- ✔ Can be integrated or work as a stand-alone

www.kahun.com

info@kahun.com



HIPAA Compliant



GDPR Compliant



SUMMARY

Kamari pharma is a clinical stage biotechnology company developing oral and topical drugs for the treatment of rare and severe genetic skin disorders such as Olmsted syndrome, Keratoderma and Ichthyosis. Kamari's drugs are based on proprietary small molecules that modulate TRPV3, an ion channel who plays a key role in the skin. These novel drugs are intended for helping patients with unmet clinical needs, where efficacious treatments are still unavailable. Clinical data from early stage studies in patients is promising.



SCIENTIFIC APPROACH

TRPV3 is a member of the TRP family highly expressed in skin displaying high permeability to calcium thermo-sensing and nociception. Genetic mutations in the TRPV3 gene, results in Olmsted syndrome, a serious and rare skin disorder. Kamari's leading drug candidates are potent and selective TRPV3 small molecule antagonists demonstrating high efficacy both in animal models and in patients. These molecules demonstrate normalization of skin structure and differentiation, re-formation of the barrier reduction in inflammation and pain. Kamari's novel compounds have the potential of becoming first in-class therapies. Kamari has completed Phase Ib clinical trials in patients suffering from Keratoderma, in leading medical centers in Israel and in the UK, the promising clinical results demonstrate the potential of TRPV3 inhibitor to treat these patients. A clinical trial with Kamari's oral drug candidate tested in patients, is expected to be launched during 2025.

Additional Phase II studies in patients suffering from other TRPV3 related skin disorders are in preparation as well.



CLINICAL INDICATIONS

In addition to hereditary Olmsted syndrome, TRPV3 is developing treatments for severe other genetic skin diseases such as Keratodermas and Ichthyosis for which no approved treatments are available. Thus, providing the opportunity for Kamari to be the first company with a drug for these markets, benefit from orphan drug designation and change the lives of many patients around the world. Kamari has received several orphan drug designations from FDA and EMA, in the space of these rare skin diseases.



CORPORATE

Kamari's shareholders are leading healthcare venture capital investors including Pontifax, Arkin, GIBF and Wille Finance. Kamari is currently seeking additional investors. Kamari's intellectual property includes approved patents that cover composition of matter claims for all its compounds and their clinical applications. Kamari Pharma is based in the Weizmann Science park in Israel.

TEAM

Kamari is led by an experienced and professional management team, with extensive experience in dermatological and rare disease drug development. The team includes Liora Braiman, PhD, Chief Scientific Officer, who has vast experience in dermatology drug development, Asaf Yarkoni, CPA, CFO, and Dayana Michel, MD, VP of Medical development. David Aviezer, Ph.D., MBA, serves as Kamari's CEO and Chairman. David was previously CEO of Protalix Biotherapeutics, who led it to FDA drug approval and listing on the New York Stock Exchange.

The Company is supported by an international team of advisors, including medical and academic key opinion leaders in the field of genetic skin disorders and dermatology.

© 2024 KAMARI PHARMA

Pinchas Sapir 3, Weizmann Science park, Ness Ziona, Israel | +972. 8. 8532774 | info@kamaripharma.com | www.kamaripharma.com


Longevity Dashboard

Operating system for proactive care



Longevity

App Personal lifestyle compass



Our Product

Medicine 3.0, powered by Longevity AI

Traditional "Medicine 2.0" is often reactive, treating patients after risks emerge. Longevity AI ushers in "Medicine 3.0" - a proactive, data-driven approach that identifies risks early, empowering clinicians to deliver preventive care.

Adaptive to the spectrum of primary care

Whether it's classic primary care, executive health programs, or concierge medicine, Longevity AI integrates seamlessly into your clinical workflow, enhancing efficiency and optimizing care at every level.

Advanced personalized AI

Bound by evidence-based medicine and leveraging big data research, Longevity AI helps practitioners catch the early signs of disease. By integrating top behavioral algorithms from the AdTech and gaming industries, Longevity AI allows you to deliver a hyper personalized and predictive care experience.

Our Partners

Maccabi
Healthcare Services

CLALIT

aws

ZOI-ME
powered by LONGEVITY-UK

PrimaryMD

XONE
PRECISION MEDICINE

MeMed is a leader in host response-based technologies, our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

MeMed developed the MeMed BV[®] test and the point-of-need platform MeMed Key[®] to help healthcare providers distinguish between bacterial and viral infections.

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective. Antibiotic misuse drives the emergence of antimicrobial resistance (AMR), one of the biggest healthcare challenges of our time.

The novelty of MeMed's technology is that it decodes the body's immune response to infection, the 'host response', rather than focusing on detecting the presence of a microbe. This allows robust diagnosis when the infection site is inaccessible or unknown, even when the pathogen is undetectable using conventional tests, or when the cause of infection are emerging new pathogens. It enables better informed antibiotic treatment decisions, an essential tool in the fight against resistant bacteria.

About MeMed BV[®]

MeMed BV[®] is a first-of-its-kind immune-based protein signature test, developed and validated over the course of decade-long collaborations with leading academic and commercial partners. It provides physicians with an indispensable tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV[®] measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. When run on the MeMed Key[®] platform, MeMed BV[®] provides a result within 15 minutes. MeMed BV[®] has been independently validated on thousands of patients and the results have been published in leading peer-reviewed journals (including Pediatrics, The Lancet ID, PLOS One, BMJ Peds and European Journal of Clinical Microbiology & Infectious Diseases).

About MeMed Key[®]

MeMed Key[®] is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need. It opens the way to quantification of a vast array of human proteins in healthy and disease states, where and when it actually matters. The MeMed Key[®] development program has been partially funded by the US Department of Defense and the EU Commission.

Regulatory Approvals

MeMed BV[®] and MeMed Key[®] are FDA, CE-IVD and AMAR cleared and now available in the US, EU and Israel. The technology has been cleared for both children and adults.

Manufacturing scalability

MeMed is now scaling its manufacturing capacities to support the commercialization of its host immune-response-based product portfolio with the aim of providing physicians with important patient management solutions to tackle key clinical dilemmas in the US and globally.



MOMENTIS
SURGICAL™

Robotics with a **Human Touch**™



Company Highlights

- Momentis is delivering innovative, small footprint, cost-effect surgical robotic technologies and techniques.
- Anovo is the first and only FDA de Novo approved robotic system for transvaginal gynecological indications.
- Momentis has expanded to general surgery with an approval for ventral hernia repair, focused on providing a surgical procedure that is less invasive, less traumatic and more efficient.
- Anovo has released a 2nd generation platform with added features including haptic feedback and dual-mode articulation.
- Commercial success in some of the largest US hospital IDNs including HCA and AdventHealth.



DENOV0

1ST Gen System
Transvaginal
Gynecology



510(K)

2ND Gen System
Abdominal General
Surgery

Technology Highlights


- ✓ Beyond human articulation
- ✓ Unrivaled reach
- ✓ Single-site access
- ✓ Reduced footprint
- ✓ Highly mobile device
- ✓ Fits any size OR & ASC
- ✓ Lower cost / higher margin system
- ✓ Easier set-up / prep further improves ROI
- ✓ Improved patient accessibility




The Market

Robotic surgery has taken a significant role in minimally invasive procedures and is currently a synonym for the da Vinci system by Intuitive Surgical. This system is based on the foundations of laparoscopy, where straight sticks instruments are introduced through multiple puncture wounds in the abdominal wall. The surgical robotics market is evaluated at \$56B, dominated by a single player.

Momentis' proprietary technology allows multi-quadrant reach with a single incision without creating a fulcrum at the point of entry, providing a less invasive and less traumatic way to perform surgical procedures.



Intuitive Surgical da Vinci
Straight Stick Instruments
through Multiple Ports



Momentis Anovo
Multiple Flexible Instruments
through a Single Port

Opmed OR™ From Insights to Action.



What would you do with **100 extra hours per OR annually?**



Add Procedures

For boosting revenue



Close Rooms

To reduce operating costs



Schedule Builder

- **Predict** case duration
- **Construct** the most efficient schedule
- **Optimize** for what matters to you



Block Architect

- **Predict** underutilization
- **Notify** and release
- **Create** and allocate



PACU

- **Predict** staff shifts
- **Predict** bay requirements
- **Proactively detect** overcapacity



Opmed Sidekick

With you every step of the way. Sidekick lets you quickly generate tailored reports to meet your operational needs and perform daily tasks through a chat-based interface.

Integrated with



www.opmed.ai

In-patient clinical decision-making for physicians and hospital management

Causal treatment plan optimization, patient-by-patient, in real time



Clinical Variation A Burden on Patients and Healthcare Expenditures

In the U.S., clinical variation significantly burdens healthcare, leading to approximately \$200B in avoidable annual costs and escalating with each step of the patient journey. This issue arises from outdated practices, variable physician training, and poor data utilization, creating disparities in care quality and operational inefficiencies. Moreover, physician decision-making, often based on biased, cohort-level information, fails to optimize individual patient treatments.

Current solutions, reliant on these biases, fail to eliminate the clinical variance, obstructing the advancement towards individualized healthcare.

ProjectM Redefining In-patient Clinical Decision-making

ProjectM revolutionizes in-patient clinical decision-making by leveraging patient-mirrored cohorts to deliver real-time, individualized treatment optimizations, ensuring improved outcomes at minimized costs.

**Minimum Variance.
Maximum Care.
Minimum Cost.**

Clinical Decision-Making Platform

Real-time patient-by-patient treatment plan optimization for physicians and hospital management

Accomplished Team

Extensive experience in in-patient care settings and data science

Existing Partnerships



Real-world evidence for decision making optimization

Real-time suggestions and predictions

Patient-by-patient optimization at every stage of the patient journey


Treatment cost minimization at every step of the patient journey

CMS TEAM Model Solution

Project M is a platform that is designed to extract the full benefits of the TEAM model, helping hospitals to optimize the economic incentives presented by the model.

Ahuva Meilik | Founder & CEO
ahuva.m@projectm.tech
+972.52.426-6068

Danny Glushenkov | coo
danny@projectm.tech
+972.52.426-6068



Theator is transforming the OR into a transparent, data-rich environment, delivering immediate ROI through additional charge capture and sustainable gains in quality and safety.

Surgery's Unseen Reality

ORs drive revenue, but remain siloed and opaque. As surgery increasingly becomes minimally invasive, most procedures use a camera. Still, footage is rarely captured or analyzed. With limited visibility, health systems are flying blind.

The Single Source of Truth

Procedural video objectively captures surgery. Leveraging proprietary computer vision and LLM capabilities, Theator's AI interprets footage and pinpoints critical steps, delivering actionable insights that augment clinical and administrative workflows.



Quality & Safety

Standardize performance, reduce variability, improve outcomes.



Efficiency

Surface untapped data, streamline processes, generate cost savings.



Documentation

Precise documentation, greater charge capture with fewer denials.



Data-driven mindset

Disseminate best practices, educate objectively, perform cutting-edge research.

Short-term Revenue, Ongoing Standardization

Billing workflow optimization produces immediate impact through increased charge capture, followed by data-driven standardization of care delivery in the longer term.

\$13,536,000*

Immediate additional charge capture through automation

\$63,475,000*

Longer-term efficiency gain through care standardization

*Potential impact on a health system with 150 ORs

Founders



Tamir Wolf, MD, PhD
CEO. Physician, ex-Israeli Navy Seal



Dotan Asselman
CTO. CV expert, ex-CV team leader in IDF 8153

Advisors



David Shulkin, MD
9th US Secretary of VA



Toby Cosgrove, MD
Former President and CEO, Cleveland Clinic



Neil Hunt
Former CPO, Netflix



Gerald Fried, MD
Past Chair, Board of Regents, ACS, McGill

IP: 27 patents and 17 pending patents across 10 jurisdictions, primarily US market

> 300K

Analyzed procedures

> 20K

Procedures analyzed monthly

> 40

AI & quality improvement publications

> 2K

Active surgeon users



MAYO CLINIC



UNIVERSITY OF MIAMI




McGill UNIVERSITY



Tel Aviv Sourasky Medical Center

www.theator.io



INTRODUCTION

UltraSight is a digital health pioneer working to **increase access to cardiac care** through the power of Artificial Intelligence (AI). Our real-time ultrasound guidance system aims to bring the benefits of cardiac imaging to more healthcare professionals in multiple care settings and allow patients easier access to cardiac treatment – addressing a significant unmet medical need in today's cardiac care landscape

PROBLEM

Point of care ultrasound (PoCUS) is one of the most important tools available in diagnosing and treating patients effectively. However, ultrasound is a unique imaging modality, and the quality of the captured image is highly dependent on the user's expertise and skills of maneuvering the probe on the patient's body.

Even with training, often new PoCUS users lack mentorship, supervision, and daily practice, making the adoption of PoCUS slow, and resulting in potential misdiagnosis, repeated exams, and operational inefficiency.

Additionally, with new advancements in cardiovascular therapeutics such as CAMZYOS™ and Herceptin™, there is a growing need for **ongoing echocardiographic monitoring** for patients beyond the hospital setting.

However, access to cardiac ultrasound is limited for many patients due to existing bottlenecks in the healthcare system and a shortage of expert sonographers, posing a real challenge for patients in need of ongoing cardiac care. In order for emerging heart medications to reach their full market potential and make an impact on patients' lives, increased access to echo monitoring within the healthcare system is needed.

SOLUTION

UltraSight is working to be well positioned to meet this unmet need. By harnessing the power of AI and applying it to point of care ultrasound devices, UltraSight's real-time guidance software empowers **medical professionals** to acquire diagnostic-quality cardiac images right where the patient is located. Images are then securely sent for remote interpretation by cardiology experts.

By separating the acquisition and interpretation of cardiac ultrasound, UltraSight can improve access to more immediate and equitable access to cardiac care for patients needing diagnosis or on going monitoring of their cardiac care regimen.

This new care delivery mode is referred to as **"decentralized cardiac ultrasound monitoring"**, which enables accessible and cost-effective heart monitoring opportunities.





PromiseBio

Precision medicine for
immune-mediated diseases

COMPANY OVERVIEW

Promise Bio is a technology company that has developed the first broad epiproteomic analysis platform to solve one of healthcare's biggest unmet needs: enabling precision-based care for immune-mediated diseases.

The company was founded based on groundbreaking research conducted at the Weizmann Institute and is currently working with leading pharmaceutical companies and research institutes to

MANAGEMENT

- Ronel Veksler, MD, PhD, Co-Founder & CEO.
ronel@promise.bio
Former Sr. Director of Product at C2i-Genomics (acquired by Veracyte)
- Assaf Kacen, PhD, Co-Founder & CTO.
assafk@promise.bio
Former EVP Technology and COO at Evogen (NASDAQ:\$EVGN).
PhD from the Weizmann Institute of Science.
- Yifat Merbl, PhD, Scientific Co-Founder.
Professor at the Weizmann Institute of Science.
PhD and post-doc at Harvard

INVESTORS

Awz Ventures, AstraZeneca, Pfizer

PROBLEM STATEMENT

In immune-mediated diseases, the combination of limited efficacy (30%-40%) and a lack of tools to identify patients more likely to respond leads to a state where many patients do not achieve clinical remission. This is detrimental to all healthcare stakeholders, from patients to providers, payors, and pharmaceutical companies.

OUR SOLUTION

Promise Bio developed the first platform for broad epiproteomic analysis. By focusing on the most dynamic and downstream part of biological data, Promise Bio's ML-based platform provides a new way to analyze proteomic data, reveals otherwise hidden information, and turns the extracted information into actionable biological insights and predictive biomarkers.

THE MARKET

Promise Bio helps pharmaceutical companies to solve challenges related to complex chronic diseases by identifying biomarkers for:


- Treatment response prediction
- Disease subtype stratification
- MOA analytics
- Target identification

Promise Bio is building the largest data lake of its kind for future proprietary clinical diagnostics product development.

BUSINESS MODEL

Fee-for-platform-based-services

Ronel Veksler, CEO | ronel@promise.bio | www.promise.bio



The Eye-D Insert

Sub-conjunctival Sustained Release Insert for Glaucoma Treatment

Our Solution



Safe bio-absorbable, sub-conjunctival insert

Quick & simple in-clinic procedure

3-6 months of treatment (Latanoprost derivative)

Platform for various diseases and active compounds

US Phase I/IIa promising results (Non Biodegradable)

Proven safety in rabbits - 16 Weeks (Biodegradable)

In vitro release profile results (Biodegradable)


Next Steps:

GLP safety study + GMP manufacturing [~\$2M]

Phase-II

Phase III

505(b)(2) regulatory pathway



Key Collaborators:



Prof. Avi Domb
Insert developer



Dr. Ike Ahmed
Chairman SAB

■ Yaacov@bio-light.co.il





Sullivan manages a substantial amount of legal work for Israeli companies and U.S. companies with Israeli interests. Our Israel practice team not only has deep experience representing Israeli companies, but we are one of the few U.S. firms with an office in Tel Aviv. Our presence in Tel Aviv, the hub of Israel's high-tech economy, serves as a gateway for Israeli public and private companies, entrepreneurs, investors, funds and other professionals to gain entry into the U.S. market. Our global capital markets team in Tel Aviv has extensive experience representing companies underwriters and funds in connection with offerings on the TASE and Nasdaq. Along with our teams in New York and Boston we are able to serve Israeli public companies 24/7 and help them complete an offering involving both jurisdictions in an effective, efficient and smooth manner.

Representative Life Sciences Clients:



About AWS

Since 2006, Amazon Web Services (AWS) has been the world's most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management. These services are offered in 102 Availability Zones within 32 geographic regions, with announced plans for 15 more Availability Zones and five more AWS Regions in Canada, Germany, Malaysia, New Zealand, and Thailand. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs.


IDB

Tel Aviv Sourasky Medical Center - Ichilov Shaping the Future of Healthcare


About Us

Ichilov is Israel's leading hospital and a global hub for healthcare innovation. Located in the heart of Tel Aviv, Ichilov combines cutting-edge technology with compassionate care, serving over 2 million visitors annually with the support of 9,000 dedicated employees.

 **Patients First**
1,500 Beds and 210 Clinics delivering comprehensive patient care.

 **Research Infrastructure**
The largest hospital-based genomic center, phase 1 in-patient ward and advanced cell therapy institute, four innovation centers, a data science hub, and a newly launched accelerator with financing engines.

 **Driving Clinical Innovation**
Over 3,000 clinical trials and 57 research labs shaping the future of healthcare.

 **Global Partnerships**
Collaborating with startups, pharmaceuticals, and research institutions to accelerate R&D.

 **Entrepreneurship Ecosystem**
In Tel Aviv, the 'Start-Up Nation' fosters 7,000+ startups and raised \$9B in health tech.

Redefining care with:

Regenerative Medicine:
Stem cell therapies.

Genetic Engineering:
Cell therapies for cancer, infectious, and inflammatory conditions.

AI Diagnostics:
Machine learning decision support systems.

Personalized Therapies:
OMICS-driven diagnostics.


I-NEXT: A Hub for Medical Innovation

I-NEXT DATA:	AI-driven solutions for clinical challenges.
I-NEXT Digital:	Smart technology improving patient care.
I-NEXT Therapies:	Advanced Cellular Therapies.
Ichilov Tech:	Bridging innovations to market applications.
I-NEXT Capital & I-NEXT Ventures:	Investment vehicles to fund and accelerate healthcare startups.
I-NEXT Devices Levin Centre:	Developing and testing 3D solutions for personalized care.
Ichilov International:	Global collaboration for innovation, research, and education.



Contact Us

 rnd.tasmc.org.il

 +972-3-697-3814

 mop@tlvmc.gov.il

 [ichilov-tech](https://www.linkedin.com/company/ichilov-tech)



ARC Global Innovation Platform

ACCELERATING INNOVATION IN HEALTHCARE

ARC (Accelerate, Redesign, Collaborate) Innovation, a pioneering initiative launched by Sheba Medical Center, Israel's largest hospital and a top 10 global healthcare institution, is set to transform the healthcare sector. Since its inception in 2019,

ARC has evolved into a global ecosystem of leading healthcare systems worldwide, strategic industry partners, and cutting-edge startup companies, all focusing on attaining two goals: driving large-scale transformation efforts and ensuring that innovation leads to economic growth. The ~160 members collaborate on co-innovation or co-development projects to tackle critical challenges in healthcare, such as **financial sustainability**, **workforce shortages** and **burnout**, **system inefficiencies**, and **policies and/or regulatory obstacles**. This collaborative approach keeps ARC at the cutting edge of healthcare transformation.

Since 2019, ARC Innovation has pioneered a successful approach to driving innovation that is reshaping the healthcare industry. Leveraging uniquely effective organic and open innovation models, ARC-Sheba has forged strategic partnerships with startups, healthcare providers, and investors. The results speak for themselves: over **100 startup companies** thrive within the ARC ecosystem. These startups collectively contribute to ARC's impressive valuation of **\$4.2 billion**, fueled by \$1 billion+ in funding. Notably, ARC-Sheba achieves 2-3 exits annually, including two substantial exits in 2024 totaling **\$800 million**.

Central to ARC's transformative innovations is its unwavering commitment to fostering a culture of entrepreneurship. **The Global School of Entrepreneurship (SPARC)** plays a pivotal role in this endeavor, demonstrating ARC-Sheba's dedication. SPARC is not just a program, but a platform for personal growth and development, empowering clinicians by equipping them with the skills needed to translate innovative ideas, technologies, and solutions into viable commercial products and services. By bridging the gap between research and practical application, SPARC contributes to improved patient care and better outcomes and offers clinicians the opportunity to be at the forefront of healthcare transformation. Additionally, advancing the entrepreneurship and innovation culture and streamlining commercialization processes has enabled ARC-Sheba to increase the number of startup spinoffs from 2 to 20 per year (within seven years).

<https://arcinnovation.org/>



THE NEXUS OF MIAMI'S TECH ECOSYSTEM

Where Groundbreaking Ideas Meet Passionate People

BRILLIANT MINDS WELCOME

In the heart of Wynwood, The LAB Miami is more than just a space — we are a gateway to South Florida's bustling tech scene.

The LAB is home to a vibrant community of entrepreneurs, enterprise executives, developers, creatives, and investors. We are united by a shared passion for shaping Miami's future as a global tech hub, fostering collaboration, and sparking connections that drive innovation.



THE WYNWOOD BUILDING
2750 NW 3rd Ave, Suite 24, Miami, FL 33127

 
@thelabmiami

THE
LAB
MIA

For more
information



Mini MIXiii Miami
Health-Tech.IL Organized and Led by IATI

Miami-Israel Collective: BRIDGING TECH ECOSYSTEMS

Miami-Israel Collective is an exclusive community that brings together top-tier entrepreneurs, tech executives, and investors to foster meaningful connections between Miami and Israel's innovative ecosystems. Our vision is to cultivate a vibrant tech ecosystem and infrastructure in Miami, supporting impactful events and communities.

MIAMIISRAELCOLLECTIVE.COM



Who We Are

Accelmed Partners is a **lower middle-market private equity fund** focused on **partnering** with U.S. **commercial-stage HealthTech companies generating \$10mm or more of revenue.**

For **more than 15 years**, we have leveraged our **deep HealthTech industry experience, operational and financial expertise and strong relationships** to help companies across the medical device, tools, diagnostics, digital health and tech-enabled services sectors position their businesses for **future growth and success.**

Our Strategy

Control Investment

- Companies with \$20 - \$70mm in TTM sales
- Initial equity check typically in range of \$25 - \$40mm; up to \$100mm (with co-investment)
- Build partnerships with management, existing investors debt holders to build long term success
- Comfortable investing in companies with substantial operational challenges

Growth Partnership

- Companies with at least \$10mm in TTM sales with strong potential for rapid commercial adoption
- Will lead or co-lead with an initial equity check typically in range of \$15 - \$25mm; up to \$40mm
- Invest in unique, disruptive technologies with strong growth stories and established management teams

Accelmed Partners Portfolio



Includes current and realized investments from Accelmed Fund I and Fund II



Mini MIXiii Miami

Health-Tech.IL Organized and Led by IATI



IATI -Israel Advanced Technology Industries Association

89 Medinat HaYehudim St,Bldg E, Herzliya Pituach, Israel

Tel: +972 (0)73 713 6313

iati@iati.co.il, www.iati.co.il

